Mergers & Acquisitions (M&A)

28.04.2025 • News

Merck to Acquire US Biopharma Company SpringWorks Therapeutics

Merck and biopharmaceutical company SpringWorks Therapeutics, have entered into a definitive agreement for Merck to acquire SpringWorks.

10.04.2025 • News

Strategic Value Partners and Blantyre Capital Acquire OQ Chemicals

Strategic Value Partners (SVP) and Blantyre Capital Limited (Blantyre) recently announced the acquisition of OQ Chemicals (Oxea), a leading global producer and merchant of oxo chemicals.

03.04.2025 • News

HAS Acquires Cerbios-Pharma

HAS Healthcare Advanced Synthesis (HAS) recently announced the planned acquisition of Cerbios-Pharma (Cerbios), a globally recognized manufacturer of chemical and biological APIs, including antibody-drug conjugates (ADCs).

02.04.2025 • News • Energy

Ineos Energy Acquires Oil & Gas Assets from CNOOC

The completion of the deal marks the third major investment by Ineos Energy in the USA in the past three years. It increases Ineos' capital spending on energy assets in the USA to above $3 billion.

11.03.2025 • News

Sun Pharma to Acquire Checkpoint Therapeutics

Indian generic drug maker Sun Pharma agreed to acquire US immunotherapy and targeted oncology company Checkpoint Therapeutics for an upfront value of $355 million. The transaction is expected to be completed in the second quarter of 2025 and is subject to customary closing conditions.

07.03.2025 • News

Rio Tinto Completes Acquisition of Arcadium Lithium

Rio Tinto has completed the $6.7 billion acquisition of Arcadium Lithium and is now the parent company of Arcadium Lithium, which will be renamed Rio Tinto Lithium and will also include the Rincon Lithium Project.

07.03.2025 • News

Jazz Pharmaceuticals to Acquire Chimerix for $935 Million

Ireland’s Jazz Pharmaceuticals signed an agreement to acquire its compatriot Chimerix for approximately $935 million. The transaction is expected to close in the second quarter of 2025.

06.03.2025 • News

ADNOC and OMV to Create Global Polyolefins Group

OMV and ADNOC agreed to combine their Borealis and Borouge shareholdings into Borouge Group International. ADNOC has also signed a share purchase agreement with Nova Chemicals, an indirect wholly owned subsidiary of Mubadala Investment Company, to acquire 100% of Nova Chemicals for an enterprise value of $13.4 billion. In addition, ADNOC and OMV have agreed for Borouge Group International to take over Nova Chemicals after closing.

04.03.2025 • News

WE Soda Buys Soda Ash Producer Genesis Alkali

WE Soda has acquired Genesis Alkali (Alkali), the largest US-based producer of natural soda ash, from Genesis Energy in an all-cash transaction for $1.425 billion.

26.02.2025 • News

Granules India Buys Swiss CDMO Senn Chemicals

Indian pharmaceutical company Granules India has agreed to acquire Senn Chemicals, a Swiss-based contract development and manufacturing organization (CDMO) specializing in peptides. The closing of the deal, which is subject to certain conditions, is expected to occur in the first half of 2025. Financial details of the transaction were not disclosed.

21.02.2025 • News

Pritzker Private Capital Acquires Majority Stake in Americhem

US investment company Pritzker Private Capital (PPC) has agreed to acquire a majority stake in Americhem, a family-owned US manufacturer of custom color masterbatch, performance additive and engineered compound solutions.

21.02.2025 • News

FibroGen Sells Chinese Subsidiary to AstraZeneca

US-based biotechnology company FibroGen announced the sale of its China subsidiary to AstraZeneca for approximately $160 million.

20.02.2025 • News

Sanofi and CD&R Sign Share Purchase Agreement for Opella

Following completion of the required social and corporate procedures, Sanofi and CD&R have signed the share purchase agreement for the sale of a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R).

12.02.2025 • News

Novonesis Acquires Feed Enzyme Alliance Share from DSM-Firmenich

Novonesis has reached an agreement with its partner DSM-Firmenich to dissolve the Feed Enzyme Alliance and take over its sales and distribution activities, for a total cash payment of €1.5 billion. The transaction is subject to customary closing conditions.

11.02.2025 • News

Novartis to Acquire Anthos Therapeutics

Swiss drugmaker Novartis has agreed to acquire Anthos Therapeutics, a Boston, US-based biopharmaceutical company with its lead compound abelacimab, a late-stage medicine in development for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

10.02.2025 • News

Bain to Acquire Mitsubishi Tanabe Pharma for $3.3 Billion

US private equity company Bain Capital has agreed to acquire Mitsubishi Tanabe Pharma Corp. (MTPC) from Mitsubishi Chemical Group Corp. in a deal that values the business at approximately 510 billion Japanese yen ($3.3 billion).

06.02.2025 • News

Jabil Acquires CDMO Pharmaceutics International

Jabil, a global provider of engineering, manufacturing, and supply chain solutions, has acquired Pharmaceutics International (Pii), a US contract development and manufacturing organization (CDMO) specializing in early-stage, clinical, and commercial volume aseptic filling, lyophilization, and oral solid dose manufacturing. Financial details of the transaction, which was completed on Feb. 3, 2025, were not given.

29.01.2025 • News

Sage Therapeutics Rejects Biogen’s Takeover Offer

Sage Therapeutics announced that its board of directors has unanimously rejected the proposal it received from Biogen on Jan. 10, 2025, to acquire all outstanding shares of Sage not already owned by Biogen for $7.22 per share, representing an equity value of about $469 million.

22.01.2025 • News

Johnson & Johnson to Acquire Intra-Cellular Therapies

Johnson & Johnson and Intra-Cellular Therapies recently entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders.

21.01.2025 • News

Grupa Azoty Nears Sale of Polyolefins Business to Orlen

Grupa Azoty and Orlen have agreed to continue to work on the terms of a potential transaction whereby Orlen – or another entity designated by Orlen – would acquire all or a portion of the shares currently held by Grupa Azoty in Grupa Azoty Polyolefins or otherwise execute the investment.

14.01.2025 • News

Barentz Strengthens DACH Position With NCD Ingredients Acquisition

Barentz, a global specialty ingredients provider, recently announced the acquisition of NCD Ingredients, a specialty, personal, and home care ingredients distributor active in Germany, Austria, and Switzerland (DACH). The acquisition enhances Barentz’s presence in the DACH region, with a particular focus on Germany—the second-largest personal care market in EMEA.

14.01.2025 • News

IMCD Acquires Life Science Business of YCAM in South Korea

IMCD, a global distribution and formulation partner of specialty chemicals and ingredients, has agreed to acquire the personal care and pharmaceutical business of YCAM, a distributor based in South Korea.

09.01.2025 • News

GSK May Acquire Cancer Specialist IDRx for $1 Billion

In a move to expand its oncology business, GSK is nearing a $1 billion deal to buy a US biotech developing a treatment for rare gastrointestinal tumors.

07.01.2025 • News

Ashland to Sell Avoca to Mane

Ashland recently announced that it has signed a definitive agreement to sell its Avoca business to Mane. The transaction is expected to close in the calendar first quarter 2025, subject to the satisfaction of customary closing conditions.

07.01.2025 • News

Merck & Co. Acquires Vaccine Site in Ireland from WuXi

As part of its long-term plans in the country, US drugmaker Merck & Co., operating as MSD outside of North America, has acquired WuXi Biologics’ site in Dundalk, Ireland, for about $500 million. The deal was announced through Ireland’s Foreign Direct Investment Agency (IDA) and MSD’s Ireland unit.

03.01.2025 • News

Immedica to Acquire Biopharma Company Marinus

Stockholm, Sweden-headquartered global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals, a US commercial-stage pharmaceutical company developing therapies for seizure disorders, for enterprise value of approximately $151 million.

02.01.2025 • News

Hutchmed to Divest Stake in Joint Venture for $608 Million

China’s Hutchmed has agreed to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals Ltd. (SHPL) for approximately $608 million (4,478 million renminbi) in cash, to China-based private equity firm GP Health Service Capital and Shanghai Pharmaceuticals.

18.12.2024 • News

AbbVie to Buy Nimble Therapeutics for $200 Million

US biopharma AbbVie has signed an agreement to acquire US biotechnology company Nimble Therapeutics, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases.

11.12.2024 • News • Strategy

Navigating the Future of Chemical Distribution

In 2024, the chemical distribution industry is at a pivotal moment, navigating both challenges and new opportunities. As distributors grapple with a landscape shaped by shifting global trade routes, demand constraints, and digital disruption, their roles are evolving far beyond traditional bulk breaking.

03.12.2024 • News

H.B. Fuller to Further Focus Portfolio

H.B. Fuller Company, the largest pure-play adhesives company in the world, recently announced that it has signed agreements to acquire two leading medical adhesive technology companies, GEM S.r.l. and Medifill Ltd.

03.12.2024 • News

Arkema Acquires Dow's Flexible Packaging Laminating Adhesives Business

Arkema recently finalized the acquisition of Dow’s flexible packaging laminating adhesives business. This acquisition will significantly expand Arkema's portfolio of solutions for flexible packaging, positioning the company as a key player in this attractive market.

28.11.2024 • News

Roche to Buy Poseida Therapeutics for $1.5 Billion

Roche has entered into a definitive merger agreement to acquire Poseida Therapeutics, a US clinical-stage biopharmaceutical company developing donor-derived CAR-T cell therapies, in a deal valued at approximately $1.5 billion.

22.11.2024 • News

Novartis Acquires Kate Therapeutics for $1.1 Billion

Swiss pharmaceutical giant Novartis has acquired Kate Therapeutics for $1.1 billion. The San Diego, US-headquartered preclinical stage biotechnology company develops adeno-associated virus (AAV)-based gene therapies to treat inherited neuromuscular diseases.

12.11.2024 • News

ICIG Acquires European Advanced Organics Business from Valtris

International Chemical Investors Group (ICIG) has acquired the European Advanced Organics business from Valtris Specialty Chemicals. The transaction includes production plants in Tessenderlo, Belgium, and Maastricht, the Netherlands, as well as the benzyl chloride and derivatives portfolio manufactured at those sites.

11.11.2024 • News

Avid Bioservices to Be Acquired by GHO Capital and Ampersand

US-headquartered Avid Bioservices, a biologics-oriented CDMO, will be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion. The three companies have signed a corresponding agreement.

1967 more articles